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Regulated Commitment of TNF Receptor
Signaling: A Molecular Switch
for Death or Activation
1991; Zheng et al., 1995), is particularly relevant. On
resting or submaximally stimulated naive cells, TNF pro-
motes proliferation (Yokota et al., 1988) through a path-
way involving TNFR2 (Gehr et al., 1992; Tartaglia et al.,
1993b; Grell et al., 1998). However, late in activation,
Felipe X. Pimentel-MuinÄ os and Brian Seed*
Department of Molecular Biology
Massachusetts General Hospital
Boston, Massachusetts 02114
TNF induces apoptosis (Sarin et al., 1995), and a TNFR2-
dependent cell death pathway has been described thatSummary
affects activated CD8-positive cells (Zheng et al., 1995;
Alexander-Miller et al., 1998; Herbein et al., 1998). Sus-Tumor necrosis factor receptor (TNFR) superfamily
members can induce a context-dependent apoptosis ceptibility to death is controlled by prior activation, so
that T cells that have been exposed to IL-2 are proneor cell activation. However, the mechanisms by which
these opposing programs are selected remain unclear. to apoptosis, but resting cells are not (Lenardo, 1991).
A consensus signaling pathway for TNFR1-mediatedWe show that in T cells, TNFR2 (TNFRSF1B) signaling
is dramatically affected by the intracellular mediator apoptosis has been proposed and recently reviewed
(Ashkenazi and Dixit, 1998). The intracellular portion ofRIP, a protein Ser/Thr kinase required for NF-kB acti-
vation by TNFR1 (TNFRSF1A). In the presence of RIP, the receptor contains a death domain (DD) (Tartaglia et
al., 1993c) and binds other DD-containing proteins uponTNFR2 triggers cell death, whereas in the absence of
RIP, TNFR2 activates NF-kB. RIP is induced during IL2- binding of ligand. A multiprotein complex including the
DD-containing signaling effectors TRADD and RIP hasdriven T cell proliferation, and its inhibition reduces
susceptibility to TNF-dependent apoptosis. Evidence been shown to form at the receptor upon TNF engage-
ment (Hsu et al., 1995, 1996a, 1996b; Stanger et al.,that signaling outputs are shaped by intracellular con-
straints helps reconcile conflicting views of TNFR1 1995). Death domain proteins like FADD/MORT1 (Boldin
et al., 1995; Chinnaiyan et al., 1995) and RAIDD (Duanand TNFR2 as apoptotic mediators.
and Dixit, 1997) may also be aggregated to the signaling
complex and have been reported to interact throughIntroduction
N-terminal death effector domains with caspases to ac-
tivate their proteolytic activity and induce apoptosisTo date, the relative roles of TNFR1 and TNFR2 in TNF-
(Thornberry and Lazebnik, 1998).induced cell death have proven difficult to establish un-
The mechanism of TNFR2-mediated cell death, how-ambiguously. Substantial evidence supports the view
ever, remains understudied. Unlike TNFR1 and CD95,that engagement of TNFR1 can trigger apoptosis in
TNFR2 lacks a death domain, and although membersmany cell types either in the absence or presence of
of the TNF receptor±associated factor (TRAF) family ofinhibitors of RNA or protein synthesis (Engelmann et al.,
proteins (Rothe et al., 1994) have been shown to play a1990; Tartaglia et al., 1991, 1993a). These inhibitors are
role in cell death induced by receptors lacking a deathnow thought to unmask or potentiate cell death by pre-
domain (Lee et al., 1996; Force et al., 1997), the preciseventing the de novo induction of an NF-kB-dependent
effectors mediating activation of the apoptotic machin-antiapoptotic response (Beg and Baltimore, 1996; Liu
ery by TNFR2 are presently unknown. We show hereet al., 1996; Van Antwerp et al., 1996; Wang et al., 1996).
that in a human T cell line TNFR2-mediated death re-Although in many cells TNFR2 delivers signals that acti-
quires RIP and that the induction of RIP during humanvate inflammation programs (Tartaglia et al., 1991; Van-
T cell activation promotes a developmental change indenabeele et al., 1992; Rothe et al., 1994), engagement
TNFR2 signaling from NF-kB activation to apoptosis.of TNFR2 in some circumstances has been found to
have proapoptotic effects of varying magnitude, ranging
from stimulation of TNFR1-mediated apoptosis (Grell et Results
al., 1995; Vandenabeele et al., 1995; Weiss et al., 1997)
to seemingly autonomous induction of cell death (Heller Jurkat (human T cell leukemia) cells express TNFR1 but
not TNFR2 (Ting et al., 1996) and are largely insensitiveet al., 1992; Grell et al., 1993, 1995; Haridas et al., 1998).
In the search for resolution of these apparent contradic- to TNF-induced cell death (Figure 1B). To explore the
apoptotic effects of TNF in this system, we created celltions, explanations based on the different activities of
membrane versus soluble TNF (Grell et al., 1995) or on lines that express TNFR2 (Smith et al., 1990) or a mutated
form of IkB-a (IkB.DN) that behaves as a dominant-the endogenous expression of membrane TNF (Grell et
al., 1999) have been advanced. However, an equally negative regulator of NF-kB activation (Brockman et al.,
1995). Figure 1A documents the expression of theseconsistent possibility is that the outcome of TNF signal-
ing cannot be completely explained by fixed signal molecules in the resulting transfected cell lines.
In accord with results from previous reports (Wallach,transduction properties ascribed to each receptor.
Evidence that TNF plays a dualistic role in activated 1984; Tartaglia et al., 1991; Van Antwerp et al., 1996),
preincubation of cells with cycloheximide (CHX) un-T cells, which principally express TNFR2 (Ware et al.,
masks the apoptotic activity of TNFR1 (Figure 1B), and
Jurkat cells expressing IkB.DN rapidly succumb to TNF-* To whom correspondence should be addressed (e-mail: seed@
molbio.mgh.harvard.edu). induced apoptosis (Figure 1C). However, expression of
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Figure 1. TNF-Mediated Apoptosis of Jurkat Transfectants Expressing TNFR2 or IkB.DN
(A) Immunoblot analysis of transfectant cell lines. Wild-type (WT) and RIP2 Jurkat cells were stably transfected with vectors either without
insert (2) or expressing TNFR2 or a dominant-negative form (IkB.DN) of IkB-a (IkB-a S32A, S36A) (1). The presence of two TNFR2 bands is
likely due to glycosylation. Both endogenous and transfected IkB-a were detected by the antibody used. The DN form has a peptide tag at
the amino terminus that gives it a slightly higher molecular mass. IkB.DN expression blocked NF-kB activation induced by a wide variety of
stimuli (data not shown). The blots were reprobed with an anti-RIP antibody to show that levels of RIP were unaffected by transfection.
(B) Cycloheximide (CHX) unmasks TNFR1-mediated cell death in Jurkat cells. When indicated, cells were preincubated for 1 hr in 10 mg/ml
of cycloheximide, and, after that, TNF (20 ng/ml) or anti-fas/CD95 (100 ng/ml) were added for 6 hr. Upper panel: cells were stained with
Annexin-V-FITC, and the percentage of Annexin-V-positive cells was measured by flow cytometry. Lower panel: cells were lysed, and low
molecular weight DNA was fractionated on a 1% agarose gel.
(C) Cells expressing TNFR2 or IkB.DN undergo RIP-dependent apoptosis. Cells were cultured for the indicated times in the absence or
presence of 20 ng/ml of TNF or for 5 hr in the presence of 100 ng/ml of anti-CD95 antibody. Low molecular weight DNA was isolated and
analyzed as in (B). Annexin-V stainings confirmed these results and showed that cell death was always greater than 40% in those experimental
points showing DNA ladder formation (data not shown). Cell death always reached more than 80% when treatments were done overnight
(data not shown). Similar results were obtained when CHX was used instead of IkB.DN as a sensitizing agent (data not shown).
TNFR2 in Jurkat cells renders them sensitive to TNF- IkB.DN were found to be highly resistant to TNF-induced
cell death (Figure 1C), indicating that RIP is required fordependent cell death in the absence of cycloheximide
or IkB.DN (Figure 1C), suggesting the existence of a TNFR1-dependent apoptosis in this setting. RIP-defi-
cient Jurkat cells expressing TNFR2 also did not diedeath pathway resistant to NF-kB activation. An alterna-
tive explanation might be that the presence of TNFR2 when exposed to TNF but retained the capacity to un-
dergo apoptosis when triggered by CD95 (Figure 1C).compromises the efficacy of the antiapoptotic program
that prevents TNFR1 from inducing cell death, for in- Thus, cell death induced by TNF seems to require RIP
both in IkB.DN- and TNFR2-expressing Jurkat cells.stance by blocking the protective pathway itself or by
inhibiting NF-kB activation. Although RIP-null cells do not undergo apoptosis, it
remains possible that the mutant cell line harbors otherWhile the Ser/Thr kinase RIP (Stanger et al., 1995) is
required for TNFR1-mediated NF-kB induction, it has mutations that are responsible for the death-resistance
phenotype. To show that RIP itself is sufficient to correctnot been found necessary for CD95-mediated cell death
(Ting et al., 1996; Kelliher et al., 1998), and any potential the phenotypic defect, we reintroduced it into RIP-defi-
cient cells by transfection. As shown in Figure 2, tran-role it might play in TNF-dependent death in Jurkat cells
might be masked by the strong protective effect of NF- sient transfection of wild-type RIP into RIP2 cells ex-
pressing TNFR2 or IkB.DN resulted in cell death afterkB activation (Beg and Baltimore, 1996; Liu et al., 1996;
Van Antwerp et al., 1996; Wang et al., 1996). Although TNF treatment. Various mutated forms of RIP (Ting et
al., 1996) were transfected into the RIP2 cell lines to es-the parental cells bearing IkB.DN were highly suscepti-
ble, RIP-deficient cells (Ting et al., 1996) expressing tablish which elements of RIP are required for apoptosis.
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Figure 2. Transfected RIP Restores TNF-
Induced Death in RIP2 Cells Expressing Ei-
ther TNFR2 or IkB.DN
RIP2 cells expressing either TNFR2 or IkB.DN
were electroporated with a mixture of 2 mg of
a plasmid encoding GFP and 10 mg of control
vector or vector expressing either wild-type
RIP or the indicated RIP mutants (KD, kinase
domain; ID, intermediate domain; DD, death
domain). After 24 hr, cells were split, incu-
bated overnight in the presence or absence of
20 ng/ml of TNF, and analyzed for cell death
using flow cytometry. Results shown are the
average of triplicate measurements and are
representative of no fewer than three inde-
pendent experiments showing similar results.
Deletion of either the death or the intermediate domain Transfection of C terminally deleted versions of TNFR2
into Jurkat cells showed that the intracellular domainsubstantially impaired the ability of RIP to restore TNF-
induced apoptosis, whereas deletion of the kinase do- and, in particular, a fragment between amino acids 415
and 435 known to contain the TRAF2 binding site (Rothemain had an incomplete effect (Figure 2). A mutated
version of RIP lacking amino acids 391 to 422 efficiently et al., 1994), are essential for efficient TNF-induced apo-
ptosis in this system (Figure 3B). This finding is in accordrestored TNF-induced cell death (Figure 2), despite be-
ing unable to mediate NF-kB activation by TNFR1 (Ting with results in other cell types (Weiss et al., 1997; De-
clercq et al., 1998) and suggests that TNFR2 stimulateset al., 1996). The dependence of cell death on the pres-
ence or absence of the different domains was similar in the cell death pathway through a process dependent
on intracellular factors. Although these findings point tothe two systems (Figure 2), suggesting that a common
function of RIP was exploited by the two death a predominant role of TNFR2 in transmitting the apo-
ptotic signal in Jurkat cells expressing TNFR2, some re-pathways.
To weigh the possibility that TNF-induced apoptosis quirement for TNFR1 costimulation cannot be excluded.
Since Jurkat cells expressing TNFR2 show a blockadein Jurkat cells expressing TNFR2 is trivially dependent
on a TNFR1-restricted process, for example by transfer in the TNFR1 pathway to apoptosis (Figure 3A, upper
panel), cell death induced by TNFR2 appears insensitiveof ligand to TNFR1, we explored the functional anatomy
of the death response. Support for the nontrivial involve- to the degree of NF-kB activation that suffices to inhibit
apoptosis through the TNFR1 pathway (see below).ment of TNFR2 comes from studies using agonistic and
antagonistic anti-TNFR1 antibodies. Specific stimula- To further explore the mechanism by which TNF
provokes apoptosis in Jurkat cells, plasmids express-tion of TNFR1 with agonistic antibodies in Jurkat cells
expressing TNFR2 fails to induce apoptosis (Figure 3A, ing antiapoptotic proteins, including dominant-negative
FADD/MORT1 (FADD.DN), Bcl-XL, and CrmA (Boise etupper panel), whereas those antibodies are able to effi-
ciently induce cell death in cells expressing IkB.DN (Fig- al., 1993; Miura et al., 1995; Chinnaiyan et al., 1996),
were transfected into wild-type cells expressing eitherure 3A, upper panel). In addition, ligand-blocking anti-
bodies against TNFR1 substantially inhibit TNF-induced TNFR2 or IkB.DN. As shown in Figure 3C, all three pro-
teins tested were able to inhibit cell death mediated bycell death in Jurkat cells expressing IkB.DN, but not
in those expressing TNFR2 (Figure 3A, lower panel). TNFR2 and TNFR1 to a similar extent. This suggests
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Figure 3. The TNFR2 Apoptosis Pathway in T Cells
(A) Agonistic and antagonistic anti-TNFR1 antibodies define a predominant role for TNFR2 in TNF-induced apoptosis in Jurkat cells expressing
TNFR2. Jurkat cells expressing either TNFR2 or IkB.DN were incubated overnight in the presence or absence of 10 mg/ml of an agonistic
anti-TNFR1 antibody (upper panel) or with TNF (20 ng/ml) for 24 hr in the absence or presence of 50 mg/ml of a neutralizing anti-TNFR1
antibody (lower panel). The percent death was measured using flow cytometry.
(B) The TRAF2 binding region of TNFR2 is required for TNF-mediated cell death. Jurkat cells were electroporated with a mixture of 2 mg of
a plasmid expressing GFP and 10 mg of a plasmid encoding the indicated C-terminal deletions of TNFR2. After 24 hr, cells were split and
incubated overnight in the absence or presence of 20 ng/ml of TNF. Cells were subjected to flow cytometry, and the percentage of live
transfected cells was evaluated. 1, greater than 45% death; 2, less than 3% death.
(C) TNF-induced death in cells expressing TNFR2 or IkB.DN is blocked by dominant-negative FADD/MORT1 (FADD.DN), Bcl-XL, and CrmA.
Cells expressing TNFR2 or IkB.DN were electroporated with a mixture of 2 mg of CD14 expression plasmid and 10 mg of either vector alone
(VECT.) or vector bearing FADD.DN (amino acids 80±205), Bcl-XL, or CrmA. After 36 hr, cells expressing CD14 were selected using anti-CD14
magnetic beads. Equal numbers of cells were then either treated for 6 hr with 20 ng/ml of TNF or left untreated, and the extent of apoptosis
was measured by low molecular weight DNA formation.
(D) FADD accumulates in a TNFR2 signaling complex in the presence of TRAF2 and RIP. 293EBNA/T cells were transfected as indicated with
DNA mixtures containing equal amounts of plasmids expressing TRAF2, RIP, FADD.DN, and a chimeric membrane protein having an extracellular
domain comprising the human IgG1 constant region, a CD7 transmembrane domain, and either the complete intracellular domain of TNFR2
or a deleted version lacking residues 415 to 465 (spanning the TRAF2 binding site). An antiapoptotic plasmid expressing CrmA and Bcl-XL
was cotransfected in each case. Cells were lysed 36 hr after transfection, and the Ig.TNFR2 chimera were immunoprecipitated using protein
A±Sepharose. The presence of FADD.DN in the precipitates was detected by blot analysis with an antibody that recognizes the death domain
of FADD.
that TNFR2, like TNFR1, mediates apoptosis through a We performed coimmunoprecipitation studies to de-
termine whether RIP can bridge TNFR2-bound TRAF2FADD/MORT1-dependent caspase pathway that can be
inhibited by CrmA and Bcl-XL. Because the apoptotic to FADD by simultaneously interacting with both mole-
cules. Cells were cotransfected with combinations ofsignals mediated by TNFR2 require the TRAF2 binding
site, we looked for a mechanism coupling TRAF2 to plasmids expressing TRAF2, RIP, the death domain of
FADD, and a transmembrane immunoglobulin chimeraapoptosis. TRAF2 has been previously shown to bind
RIP (Hsu et al., 1996b), and RIP and FADD/MORT1 are bearing a TNFR2 intracellular domain (Figure 3D). Fol-
lowing immunoprecipitation of the TNFR2 component,known to interact (Varfolomeev et al., 1996), although
the precise geometry of these associations is not under- FADD was detected only in the presence of RIP and
only when the TNFR2 intracellular domain retains anstood.
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intact TRAF2-binding site (Figure 3D). Thus, a probable
logic for the pathway is that TNFR2 engagement leads
to the recruitment of TRAF2, association of RIP, and
binding of FADD/MORT1.
NF-kB activation initiates a response that blunts the
apoptotic action of several agonists of cell death, includ-
ing TNFR1 (Beg and Baltimore, 1996; Liu et al., 1996;
Van Antwerp et al., 1996; Wang et al., 1996). Thus, a
diminished NF-kB activation might facilitate apoptosis
through TNFR2. However, Jurkat cells expressing TNFR2
triggered a strong NF-kB response upon TNF treatment
(Figure 4A), indicating that the NF-kB-activated protec-
tive response fails to protect against TNFR2-induced
apoptosis.
Activation of NF-kB by TNFR1 has been shown to
require RIP (Ting et al., 1996; Kelliher et al., 1998), and
the RIP-null cells used here show an absolute block in
TNFR1-mediated NF-kB induction (Ting et al., 1996).
Unexpectedly, TNF was able to activate NF-kB in RIP2
cells expressing TNFR2 (Figure 4B), indicating that
TNFR2 is capable of activating NF-kB by a pathway
that intersects the TNFR1-initiated pathway somewhere
downstream of RIP. As a result, apoptosis and NF-kB
activation induced by TNFR2 are uncoupled at the level
of RIP.
These findings imply that, in T cells, RIP may be able
to determine the outcome of TNF signaling. In the ab-
sence of RIP, only TNFR2 would be functional, triggering
NF-kB activation, and both apoptosis and the induction
of NF-kB through TNFR1 would be blocked. In the pres-
ence of RIP, TNF-induced apoptosis should proceed
efficiently through a TNFR2-dependent pathway, de-
spite induction of NF-kB activity through both receptors.
This differential signaling mimics naturally occurring
events in T cell activation. Activated human and murine
T cells principally express TNFR2 (Ware et al., 1991;
Zheng et al., 1995), and TNFR2 has been found to medi-
Figure 4. NF-kB Activation Induced by TNF in Wild-Type and RIP2
ate TNF-induced proliferation in the initial phase of the Cells Expressing TNFR2
T cell activation response (Gehr et al., 1992; Tartaglia (A) TNF strongly activates NF-kB in Jurkat cells expressing TNFR2.
et al., 1993b; Grell et al., 1998). Later in the process, T Wild-type cells bearing either vector or TNFR2 expression plasmid
cells become sensitive to apoptosis induced by TNF were electroporated with a mixture of DNA containing 4 mg of an
NF-kB-luciferase reporter and 12 mg of a vector expressing both(Sarin et al., 1995), and when activated murine CD8-
CrmA and Bcl-XL. After 36 hr, cells were split into three wells andpositive cells are restimulated through the T cell recep-
treated for 6 hr with 20 ng/ml of TNF, 10 ng/ml of phorbol-12-tor, TNFR2 mediates activation-induced cell death trig-
myristate-13-acetate (PMA) plus 1 mM of ionomycin, or left un-gered by the autocrine secretion of TNF (Zheng et al.,
treated. They were then lysed, and the luciferase activity was mea-
1995). sured. Values shown are averages of triplicate measurements, nor-
To determine whether developmental regulation of malized as the fraction of luciferase activity induced by treatment
RIP controls susceptibility to cell death in vivo, we stud- with PMA/ionomycin.
(B) RIP is not required for TNFR2-mediated activation of NF-kB.ied TNF sensitivity and RIP expression in activated T
RIP2 cells transfected with either vector or TNFR2 expression plas-cells from multiple human donors. Both CD4- and CD8-
mid were electroporated with an NF-kB-luciferase reporter plasmidpositive cells are resistant to TNF-induced apoptosis 2
(4 mg). After 16 hr, cultures were exposed for 6 hr to either 20 ng/days after phytohemagglutinin (PHA) stimulation (Figure
ml of TNF, 10 ng/ml of PMA plus 1 mM of ionomycin, or no agent.
5A). At this time, NF-kB activation, measured as nuclear Luciferase assay and normalization were conducted as described
translocation of the p65 (RelA) subunit of NF-kB, is intact in (A).
(Figure 5B), and cells express TNFR2 (Figure 5C). How-
ever, after the cells are cultured 4±10 more days in
RIP expression is strongly induced in human T cellsthe presence of IL-2, they become susceptible to TNF-
between day 2 and day 10 of activation (Figure 5D) withinduced cell death (Figure 5A), while retaining unchanged
good expression apparent by day 5 (data not shown).their ability to activate NF-kB (Figure 5B). The transition
To evaluate whether RIP expression may be necessaryto a death-sensitive state occurs without significant vari-
for apoptosis in this context, we developed a system toation in the expression of TNFR2 (Figure 5C) or FADD
interfere with RIP expression and measure its impact(Figure 5D), and TNFR1 expression remains undetect-
on TNF-induced cell death. Since the RIP-deficient miceable throughout (data not shown). Consistent with previ-
have a perinatal lethal phenotype (Kelliher et al., 1998)ous reports (Sarin et al., 1995), the presence of IL-2
during TNF treatment inhibits cell death (Figure 5A). and it has not been possible to create T cell lines from
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Figure 5. Analysis of TNF-Induced Cell Death and NF-kB Activation during Human T Cell Activation
(A) Activated T cells acquire sensitivity to TNF-induced cell death after IL2 exposure. Peripheral blood mononuclear cells (PBMCs) were
purified and activated with 2 mg/ml of PHA for 2 days. CD4 and CD8 cells were purified with magnetic beads and subsequently incubated
for 8 days in the presence of 30 U/ml of IL-2. At the indicated times, cells were harvested, washed, and incubated for 72 hr in the absence
or presence of 50 ng/ml TNF. Where indicated, 30 U/ml of IL-2 was present during TNF treatment. Cell death was evaluated by Annexin-V-
FITC staining.
(B) TNF-induced NF-kB activation does not change during T cell activation and proliferation. Cells were activated, purified using a mixture of
CD4- and CD8-specific magnetic beads, and cultured as above. Day 2 or day 10 cells were collected, washed, and incubated overnight to
reduce spontaneous activation of NF-kB. T cells were then treated with TNF (50 ng/ml) for the indicated times and lysed, and nuclear extracts
were isolated. Equal amounts of nuclear protein were subjected to SDS-PAGE, and the p65 (RelA) subunit was detected by immunoblot.
(C) TNFR2 expression does not vary significantly during IL-2-dependent human T cell expansion. Cells were activated with PHA, purified and
cultured as in (A) with the exception of TNF treatment, and subjected to flow cytometry using an anti-TNFR2 or an irrelevant control antibody.
Shown is the mean fluorescence intensity (MF) obtained with anti-TNFR2 antibody (light line).
(D) RIP expression is induced during IL-2-dependent T cell expansion, whereas FADD expression remains constant. Cells were activated and
purified as in (C), washed, and lysed in a buffer containing 1% NP-40. Extracts were normalized for protein content, and equal amounts of
protein were loaded in each well, resolved by SDS-PAGE, and subjected to immunoblotting using a specific anti-RIP antibody. Western blots
were reprobed with an anti-FADD specific antibody.
such mice to date, we explored alternative approaches expressing construct or cells expressing GFP only (Fig-
ure 6B). Similar constructs bearing an irrelevant anti-based on retroviral transfer of antisense constructs. Be-
cause RNAs that lack open reading frames are known sense segment downstream of GFP lacked death-pro-
tective activity, indicating that the effect is specific toto be labile, we inserted a green fluorescent protein
(GFP) coding sequence upstream of antisense RIP in a antisense RIP (Figure 6C).
Thus, the findings in primary human T cells are consis-murine leukemia virus±based vector (Riviere et al., 1995).
An improved efficiency of the GFP-RIP antisense tran- tent with observations from experiments with Jurkat
cells. In human T cells, RIP is needed for TNFR2 induc-script over conventional antisense RNA was apparent
in the inhibition of cell death provoked by overexpres- tion of death but not NF-kB activation. In resting T cells
or activated T cells that have not been exposed to IL2,sion of RIP in 293T cells (Figure 6A). Retroviral transduc-
tion of the GFP-antisense RIP transcription unit into TNF activates NF-kB through TNFR2 and a TRAF2-
dependent pathway (Rothe et al., 1995). In activated TCD8 T cell blasts from four different donors decreased
susceptibility to TNF-induced cell death at day 10 after cells that have been exposed to IL2, RIP is induced and
is proposed to bridge the TNFR2±TRAF2 complex toactivation, as established by comparison with cells not
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Figure 7. Context-Dependent TNF Signal Transduction
(A) The role of RIP in T cells. Early in T cell activation, the expression
of RIP is low and TNFR2 induces NF-kB activation. Following expo-
sure to IL2, RIP expression increases and, through TRAF2 or related
TRAF-like factors, bridges TNFR2 to FADD/MORT1 and the apo-
ptotic machinery.
(B) Differences in signaling in fibroblasts and T cells. In fibroblasts,
Figure 6. Retroviral Transduction of RIP Antisense Inhibits the IL2- RIP is essential for TNFR1-mediated NF-kB activation, but not
Driven Transition of CD8 T Cells to a Death-Sensitive State death. In T cells, RIP is required for TNFR1-dependent NF-kB activa-
tion and death and for TNFR2-mediated death, but not NF-kB activa-(A) Potentiation of antisense activity by an upstream open reading
tion. TNFR2-dependent death is unaffected by NF-kB activation inframe. 293T cells were transfected as indicated with 10 mg of a
this setting.mixture of mammalian expression plasmids containing GFP (2 mg),
RIP (2 mg), and either antisense RIP or a construct containing the
GFP open reading frame upstream of antisense RIP (GFP-RIP anti-
sense) (6 mg). The percentage of GFP-positive cells undergoing FADD/MORT1 and the apoptosis machinery (Figure 7A).
apoptotic cell death versus the total number of GFP-positive cells Although in human T cells, RIP is needed for TNFR1-
was scored 36 hr after transfection.
mediated induction of both death (this work) and NF-(B) GFP-RIP antisense inhibits TNF-induced apoptosis in CD8 T cell
kB activation (Ting et al., 1996), its action downstreamblasts. PBMCs from four independent donors were isolated and
of TNFR1 clearly depends on cell type. Mouse fibro-cultured in the presence of PHA as described in Figure 5. After 2
days, cells were transduced overnight with retrovirus expressing blasts are normally resistant to TNFR1-induced apo-
either GFP or GFP-RIP antisense. A day later, CD8-positive cells ptosis but are sensitive when RIP is absent (Kelliher et
were isolated using magnetic beads and cultured for 8 days in the al., 1998), suggesting that in these cells RIP is required
presence of IL2 (30 U/ml) to induce competency for TNF-triggered
for the NF-kB protective response, but not for TNFR1-cell death. Apoptosis assays were performed with Annexin-V-phy-
mediated cell death (Figure 7B). Thus, there are likelycoerythrin. The death-protective activity was assessed for each cul-
lineage-specific differences in the TNFR1 signalingture by comparison of the percent death in the transduced (green)
and nontransduced (nongreen) cells. Data for the antisense con- pathway as well.
structs are presented as a percentage of the death protection (nil)
provided by GFP transduction alone. Discussion
(C) Antisense CD59 or CD44H do not significantly interfere with TNF-
induced apoptosis of CD8 T cell blasts. Cells were cultured and
An implicit assumption in many signal transductionprocessed as in (B) with the exception that GFP and GFP-CD59
studies has been that a single consensus sequence ofantisense or GFP and GFP-CD44H antisense constructs were used
to transduce activated PBMCs. Susceptibility to TNF-induced apo- events suffices to account for the majority of changes
ptosis was calculated as in (B). in cellular state that follow exposure to an extracellular
mediator. Indeed, for the signaling induced by G protein±
coupled receptors, there appears to be a reasonable
likelihood that this model is valid and that the varying
Immunity
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responses of cells to different ligands can largely be and the B cell differentiation and survival (Banchereau
predicted on the basis of the varying complement of et al., 1991) receptor CD40 also mediates apoptosis
cell surface receptors exhibited by the responding cells. (Hess and Engelmann, 1996). The receptor for lympho-
However, it is unclear how general this phenomenon toxin-b induces NF-kB activation (Mackay et al., 1996)
may be, and there is reasonable evidence to suggest but triggers cell death in the presence of g interferon
that in cell death pathways, and particularly in the im- (Browning et al., 1996). In the central nervous system,
mune system, the model has limited power to explain the low affinity nerve growth factor receptor has been
the observed phenomena. implicated both in induction of cell death by default
Cell populations in the immune system undergo (absence of ligand) (Rabizadeh et al., 1993) and in ligand-
expansion and contraction in the absence of the cell±cell dependent survival and NF-kB activation (Rabizadeh et
and cell±matrix contacts that normally regulate cell num- al., 1993; Carter et al., 1996). Thus, throughout the TNF
ber in solid organs. Hence, regulatory mechanisms that receptor superfamily one finds examples that death and
function in the absence of specific organ context cues activation represent alternative programs conditioned
are required, and in this context the apposite control on receptor context and cell state.
of apoptotic cell death (Winoto, 1997) is an important As these examples show, it cannot be assumed that
theme. In theory, population expansion and contraction a consensus pathway applies to all cells and under all
can be controlled by coupling proliferative signals with conditions, and hence it is clearly necessary to appreci-
an invariant death program, and indeed, at one extreme, ate signaling pathways in a cell-specific context. Unfor-
neutrophilic granulocytes, the most vigorously prolifer- tunately, this considerably complicates any discussion
ating cells in the immune system, are committed by of signaling and creates a burden to establish the basic
default to constitutive proliferation and an apoptotic fate constituents of the signaling pathway in each cell type
(Savill, 1997). and under each set of experimental circumstances. On
But more sophisticated controls appear necessary the other hand, considering the breadth of expression
to manage clonal populations that must increase and of these receptors and the diversity of roles they sub-
decrease in response to specific stimuli. Studies in mice serve, the elucidation of the cell-specific features of their
have shown that IL-2, an important cytokine for clonal signal transduction is likely to shed new light on their
expansion, also programs T cells for eventual death functions in normal and deranged physiology.
(Lenardo, 1991). The significance of this observation
has been underscored by findings that mice deficient Experimental Procedures
in either the IL-2 gene or the genes for the b or g chains
Cells and Transfectionsof the IL-2 receptor show lymphoproliferative disorders
Jurkat cells and the electroporation methods used in this study have(Sadlack et al., 1993; Suzuki et al., 1995; Nakajima and
been described in detail elsewhere (Ting et al., 1996). AdherentLeonard, 1997). These reports conflict with the simple
cells were transfected by using the calcium phosphate precipitation
view that the sole function of IL-2 is expansion of acti- method as previously described (Ausubel et al., 1987).
vated populations and point to an important role for Flag-tagged IkB-a S32A, S36A (Brockman et al., 1995), and TNFR2
IL-2 signaling in population contraction in the murine (Smith et al., 1990) cDNAs were subcloned into a mammalian epi-
somal expression plasmid that contains a puromycin resistance.immune system. Our results suggest that in humans IL-2
To create stable transfectants, cells were electroporated with themay have a similar role, promoting T cell proliferation
indicated plasmids and subjected to puromycin (Sigma, St. Louis,as well as the transition to a death-susceptible state.
MO) selection (1 mg/ml) for 10 days. Cells were further purified byTNF enters the picture in a dualistic role, acting as an
limiting dilution to obtain clonal populations.
activating cytokine early in immune arousal and as an Peripheral blood mononuclear cells (PBMCs) were purified by
apoptotic cytokine following IL-2 removal. centrifugation onto a Ficoll/diatrizoate cushion (Organon Teknika,
In T cells, antigen receptor activation and prolifera- Durham, NC) and activated with 2 mg/ml of PHA (Sigma). Purification
of CD4- and CD8-positive cells was performed using Dynabeadstion are different programs. Antigen receptor engage-
and the Detachabead system (Dynal, Oslo, Norway). Purity, activa-ment does not lead directly to cell cycle transition but
tion, and TNFR expression were determined by flow cytometryinduces competency for proliferation by activation of
(Coulter Epics XL), using anti-CD3, -CD4, -CD8, -CD25, -CD69 (Phar-both cytokine and cytokine receptor promoters. The Mingen, San Diego, CA), or anti-TNFR2 (R and D Systems, Minneap-
data presented here indicate that the death susceptibil- olis, MN) antibodies. Purity was always greater than 95%. After
ity program is associated with proliferation instead of purification, as indicated, cells were further cultured in the presence
activation, as RIP induction occurs during the IL-2- of 30 U/ml IL-2 (Sigma).
driven proliferation phase, not the early activation re-
Immunoblotting and Coimmunoprecipitation Studiessponse. Because RIP is required for both the death and
To measure TNFR2, IkB.DN, or RIP expression in the Jurkat stableNF-kB induction activities mediated by TNFR1 in T cells,
transfectants, equal numbers of cells were harvested and directly
TNFR1, if present, is unlikely to contribute significantly lysed in 23 reducing SDS sample buffer. To measure RIP and FADD
to TNF signaling prior to RIP induction. expression levels in human primary T cells, cells were lysed on ice
The dual capacity to induce activation and apoptosis for 20 min in a buffer containing 1% NP-40 (Sigma). To evaluate
appears to be a common property of ligands of the TNFR NF-kB activation in primary T cells, nuclear extracts were obtained
after TNF treatment, basically as previously described (Schreiber etsuperfamily. For example, CD95 aggregation triggers
al., 1989). Protein concentrations were measured by the bicinchoni-efficient cell death (Itoh et al., 1991) but also proliferation
nic acid method (Pierce, Rockford, IL). For the coimmunoprecipita-(Alderson et al., 1993) and NF-kB activation (Ponton
tion studies, 293EBNA/T cells were transfected with the indicated
et al., 1996). CD27 engagement can stimulate T cell DNAs and lysed 36 hr later in a buffer containing 0.1% NP40 as
proliferation (Goodwin et al., 1993) but can also mediate described previously (Hsu et al., 1995). The Ig.TNFR2 intracellular
apoptosis (Prasad et al., 1997). CD30 ligand is able to domain chimera were immunoprecipitated with protein A±Sepharose
(Sigma) for 3 hr at 48C. Precipitates were washed twice with lysisinduce both proliferation and death (Smith et al., 1993);
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buffer, twice with lysis buffer containing 0.8 M NaCl, and twice more were activated for 48 hr with 2 mg/ml of PHA. Virus-enriched super-
natants were collected 48 hr posttransfection and diluted 1:1 in thewith lysis buffer. In all cases, equivalent amounts of protein were
resolved by SDS-PAGE, electrophoretically transferred to a PVDF PHA conditioned media (total volume of 3 ml). Cells (2 3 107 per
experimental point) were resuspended in this mixture and addedmembrane (Immobilon, Millipore, Bedford, MA), and probed with
specific antibodies against TNFR2 (R and D Systems), IkB-a (Santa onto a 6 cm plate that was previously coated with a recombinant
fibronectin fragment (RetroNectin, Takara Biomedicals, Shiga, Ja-Cruz, Santa Cruz, CA), RIP, FADD/MORT1, or p65 NF-kB (Transduc-
tion Laboratories, Lexington, KY). pan), following the instructions of the manufacturer. Transductions
were done overnight. The next day, cells were harvested and CD8-
positive cells purified by using magnetic beads (Dynal). Transduc-
Apoptosis Assays tion efficiencies ranged from 15% to 25% in the case of GFP and
Annexin-V stainings were carried out following the instructions pro- from 5% to 15% in the case of the GFP-RIP, CD59, or CD44H
vided by the manufacturer (R and D Systems). DNA fragmentation antisense constructs. The transduced CD8 cells were cultured for
assays were performed on 5 3 106 cells per experimental point, 8 more days in the presence of 30 U/ml of IL2, washed and incubated
essentially as described previously (Herrmann et al., 1994). Low for 72 hr in the absence or presence of 50 ng/ml of TNF, and stained
molecular weight DNA was resolved on a 1% agarose gel. Cyclohexi- with Annexin-V-phycoerythrin (PharMingen).
mide and TNF were purchased from Sigma and the anti-Fas antibody
(IgM clone CH-11) from UBI (Lake Placid, NY).
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